SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: S-3
Document Type: EX-1.2
Date Filed: 2025-11-26
Accession Number: 0001213900-25-115554
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390025115554/ea026681201ex1-2_synergy.htm

Chunk 10 of 18
Word Count: 1321
Character Count: 8495

Document Content:

provide a Representation Date Certificate shall be waived for any Representation Date occurring at a time at which no Placement Notice is pending, which waiver shall continue until the earlier to occur of the date the Company delivers a Placement Notice hereunder (which for such calendar quarter shall be considered a Representation Date) and the next occurring Representation Date; provided, however, that such waiver shall not apply for any Representation Date on which the Company files its Annual Report on Form 10-K. Notwithstanding the foregoing, if the Company subsequently decides to sell Placement Shares following a Representation Date when the Company relied on such waiver and did not provide the Agents with a Representation Date Certificate, then before the Company delivers the Placement Notice or the Lead Agent sells any Placement Shares, the Company shall provide the Agents with a Representation Date Certificate, dated the date of the Placement Notice.

(n) Legal Opinion.
On the date of effectiveness of the Registration Statement, the Company shall cause to be furnished to the Agents a written opinion and
negative assurance letter of Nelson Mullins Riley & Scarborough LLP (“Company Counsel”), or other counsel satisfactory
to the Agents, in form and substance satisfactory to the Agents and their counsel. Thereafter, within five (5) Trading Days of each Representation
Date with respect to which the Company is obligated to deliver a Representation Date Certificate for which no waiver is applicable, the
Company shall cause to be furnished to the Agents a negative assurance letter of Company Counsel in form and substance satisfactory to
the Agents and their counsel; provided however, if no Placement Notice is pending at such Representation Date, then before the Company
delivers a Placement Notice or the Agents sells any Placement Shares, the Company shall provide the Agents with such negative assurance
letter; provided, further, that in lieu of such negative assurance letter for subsequent periodic filings under the Exchange Act, Company
Counsel may furnish the Agents with a letter (a “Reliance Letter”) to the effect that the Agents may rely on a prior
negative assurance letter delivered under this Section 7(n) to the same extent as if it were dated the date of such letter (except
that statements in such prior negative assurance letter shall be deemed to relate to the Registration Statement and the Prospectus as
amended or supplemented as of the date of the Reliance Letter).

(o) Comfort
Letter. (1) On the date of this Agreement and (2) within five (5) Trading Days of each Representation Date, with respect to which
the Company is obligated to deliver a certificate in the form attached hereto as Exhibit 7(m) for which no waiver is applicable, the Company
shall cause its independent accountants to furnish the Agents letters (the “Comfort Letters”), dated the date the Comfort
Letter is delivered, which shall meet the requirements set forth in this Section 7(o); provided however, if no Placement Notice
is pending at such Representation Date, then before the Company delivers a Placement Notice or the Lead Agent sells any Placement Shares,
the Company shall provide the Agents with the Comfort Letter; provided, further, that if requested by the Agents, the Company shall cause
a Comfort Letter to be furnished to the Agents within ten (10) Trading Days of the date of occurrence of any material transaction or event,
including the restatement of the Company’s financial statements. The Comfort Letter from the Company’s independent accountants
shall be in a form and substance satisfactory to the Agents,

(i) confirming that
they are an independent public accounting firm within the meaning of the Securities Act and the Public Company Accounting Oversight Board
(the “PCAOB”),

(ii) stating,
as of such date, the conclusions and findings of such firm with respect to the financial information and other matters ordinarily covered
by accountants’ “comfort letters” to underwriters in connection with registered public offerings (the first such letter,
the “Initial Comfort Letter”) and

(iii) updating
the Initial Comfort Letter with any information that would have been included in the Initial Comfort Letter had it been given on such
date and modified as necessary to relate to the Registration Statement and the Prospectus, as amended and supplemented to the date of
such letter.

(p) Chief
Financial Officer’s Certificate. (1) On the date of this Agreement and (2) within five (5) Trading Days of each Representation
Date, with respect to which the Company is obligated to deliver a Representation Date Certificate for which no waiver is applicable, the
Company shall have delivered to the Agents a certificate executed by the Chief Financial Officer of the Company (“CFO Certificate”)
dated as of such date, in form and substance reasonably satisfactory to the Agents.

(q) Market
Activities. The Company will not, directly or indirectly, (i) take any action designed to cause or result in, or that constitutes
or might reasonably be expected to constitute, the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of Common Stock or (ii) sell, bid for, or purchase Common Stock, or pay anyone any compensation for soliciting purchases
of the Placement Shares other than the Agents.

(r) Investment
Company Act. The Company will conduct its affairs in such a manner so as to reasonably ensure that it will not become, at any time
prior to the termination of this Agreement, an “investment company,” as such term is defined in the Investment Company Act.

Offer to Sell. Other than an Issuer Free Writing Prospectus approved in advance by the Company and the Agents in their capacity as
agents hereunder, none of the Agents nor the Company (including its agents and representatives, other than Agents in their capacity as
such) will make, use, prepare, authorize, approve or refer to any written communication (as defined in Rule 405 under the Securities Act),
required to be filed with the Commission, that constitutes an offer to sell or solicitation of an offer to buy Placement Shares hereunder.

(t) Sarbanes-Oxley
Act. The Company will, use commercially reasonable efforts to maintain and keep accurate books and records reflecting its assets and
maintain internal accounting controls in a manner designed to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance with GAAP and including those policies and procedures
that (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions
of the assets of the Company, (ii) provide reasonable assurance that transactions are recorded as necessary to permit the preparation
of the Company’s consolidated financial statements in accordance with GAAP, (iii) that receipts and expenditures of the Company
are being made only in accordance with management’s and the Company’s directors’ authorization, and (iv) provide reasonable
assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that
could have a material effect on its financial statements. The Company will use commercially reasonable efforts to maintain such controls
and other procedures, including, without limitation, those required by Sections 302 and 906 of the Sarbanes-Oxley Act, and the applicable
regulations thereunder that are designed to ensure that information required to be disclosed by the Company in the reports that it files
or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s
rules and forms, including, without limitation, controls and procedures designed to ensure that information required to be disclosed by
the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management,
including its principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to
allow timely decisions regarding required disclosure and to ensure that material information relating to the Company is made known to
it by others within the Company, particularly during the period in which such periodic reports are being prepared.